Sequence: Ac-Tyr-Lys-Leu-Dpg-Leu-Lys-Leu-Dpg-Leu-Lys-Dpg-Leu-Lys-Leu-Dpg-Leu-Lys-NH2
| Experiment Id | EXP001535 |
|---|---|
| Paper | An Amphipathic Structure of a Dipropylglycine-Containing Helical Peptide with Sufficient Length Enab |
| Peptide | Pep4 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 100 nM |
| Mixing Ratio | N/P = 8 |
| Formulation Format | electrostatic peptide/siRNA complexes (CPP nanoparticles) |
| Formulation Components | Pep4 + siRNA (Luc or Scr) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Huh-7-Luc (luciferase-expressing human hepatoma cells; 10% FBS media) |
| Animal Model | |
| Administration Route | |
| Output Type | RNAi (luciferase assay, 24 h) |
| Output Value | ~85% luciferase knockdown at N/P=8 vs Scr control (24 h). |
| Output Units | |
| Output Notes | Pep4 at higher N/P improved knockdown compared with N/P=4 in serum-containing medium. |
| Toxicity Notes | No major cytotoxicity reported for Pep4 at N/P=8 compared with other peptides. |
| Curation Notes |